all-trans retinoic acid (ATRA)

Phase 3Small molecule

Incyte

all-trans retinoic acid (ATRA) is one of 186 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

LeukemiaActive, not recruiting

Acute Promyelocytic LeukemiaActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Sclerosing CholangitisActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

LeukemiaPhase 1/Phase 2

Active, not recruiting

Acute Promyelocytic LeukemiaPhase 3

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Sclerosing CholangitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

all-trans retinoic acid (ATRA)

Incyte

Phase 3

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Not yet recruiting

Arsenic Trioxide

NCT07296445

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Completed·UUniversity of Ulm·Phase 3·NCT01237808·144 enrolled

Multiple Myeloma1 trial

Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01985477·2 enrolled

Relapsed/Refractory AML1 trial

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Completed·WWashington University School of Medicine·Phase 1·NCT01161550·11 enrolled

OIC1 trial

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00413166·78 enrolled

Arsenic Trioxide1 trial

A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)

Not yet recruiting·SSDK Therapeutics, Inc.·Phase 3·NCT07296445·120 enrolled

9 more indications

Completed·AAmsterdam UMC, location VUmc·Phase 1/2·NCT02751255·60 enrolled

Leukemia1 trial

Differentiation Induction in Acute Myelogenous Leukemia

Completed·UUniversity of Bergen·Phase 1/2·NCT00175812·24 enrolled

Advanced Malignancies1 trial

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02712905·116 enrolled

Azacytidine1 trial

Phase II 5-Azacytidine Plus VPA Plus ATRA

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00326170·34 enrolled

Sclerosing Cholangitis1 trial

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Completed·YYale University·Phase 1·NCT01456468·19 enrolled

Unspecified2 trials

"AIDA" Protocol (LAP 0493)

Unknown status·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT01064557·1,068 enrolled

AIDA 2000 Guidelines

Unknown status·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT01064570·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for all-trans retinoic acid (ATRA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — all-trans retinoic acid (ATRA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for all-trans retinoic acid (ATRA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte

all-trans retinoic acid (ATRA)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Multiple Myeloma1 trial

Relapsed/Refractory AML1 trial

OIC1 trial

Arsenic Trioxide1 trial

Acute Promyelocytic Leukemia1 trial

SCLC1 trial

Lung Cancer1 trial

Daratumumab1 trial

Leukemia1 trial

Advanced Malignancies1 trial

Azacytidine1 trial

Sclerosing Cholangitis1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News